These Funding Opportunity Announcements (FOA) and/or Notice of Special Interests (NOSI) are associated with the Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, these FOAs and/or NOSI target the following area designated as scientific priority by the Blue Ribbon Panel (BRP):
Recommendation C. Develop ways to overcome cancer’s resistance to therapy
Identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.
The goal of these FOA and/or NOSI is to, through administrative supplement, encourage new interdisciplinary collaborations between outside (non-DSRN-supported) investigators and DSRN U54-supported investigators to perform research within the scientific scope(s) of their active parent grant(s) and/or cooperative agreement award(s). These collaborations between applicants and a DRSN U54 center are expected to lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.
The detailed information of DRSN Revision Project awardees is available at DRSN members.